SCHEMBL4354515

SCHEMBL4354515

O=C(Nc1ccc(O)c(Cl)c1)Oc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.69
ALDH1A1 P00352 6/20 0.69
KDM4E B2RXH2 4/20 0.69
POLB P06746 2/20 0.68
RAD51 Q06609 2/20 0.55
CYP1A2 P05177 2/20 0.55
KMT2A Q03164 6/20 0.52
MEN1 O00255 4/20 0.52
THRB P10828 1/20 0.52
GFER P55789 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
LMNA P02545 2/20 0.51
GAA P10253 2/20 0.51
TP53 P04637 1/20 0.51
TRPV1 Q8NER1 1/20 0.51
CYP2D6 P10635 2/20 0.50
HSD17B10 Q99714 2/20 0.50
ATM Q13315 1/20 0.50
USP2 O75604 1/20 0.50
BRD4 O60885 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11175842 0.88 POLB (0.72) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL30063430 0.88 POLB (0.72) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL4345396 0.84 POLB (0.63) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL61187 0.84 POLB (0.71) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL17868230 0.84 POLB (0.67) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL24969471 0.83 POLB (0.65) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL8601506 0.82 MAPT (1.00) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL31028641 0.81 POLB (1.00) MAPTALDH1A1POLBCYP1A2KMT2A
SCHEMBL11131058 0.81 POLB (0.63) MAPTALDH1A1KDM4EPOLBRAD51
SCHEMBL2490151 0.81 POLB (0.67) MAPTALDH1A1KDM4EPOLBRAD51

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN disclosed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP disclosed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO disclosed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAPT 4439/4885ALDH1A1 2565/4885KDM4E 2662/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MAPT 4184/4885ALDH1A1 2767/4885KDM4E 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.